Literature DB >> 9455502

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

W A Craig1.   

Abstract

Investigations over the past 20 years have demonstrated that antibacterials can vary markedly in the time course of antimicrobial activity. These differences in pharmacodynamic activity have implications for optimal dosage regimens. The results of more recent studies suggest that the magnitude of the pharmacokinetic/pharmacodynamic parameters required for efficacy are relatively similar in animal infection models and in human infections. However, there is still much to learn. Additional studies are needed to further correlate pharmacokinetic/pharmacodynamic parameters for many antibacterials with therapeutic efficacy in a variety of animal infection models and in human infections. The potential value of using pharmacokinetic/pharmacodynamic parameters as guides for establishing optimal dosing regimens for new and old drugs and for new emerging pathogens and resistant organisms, for setting susceptibility breakpoints, and for reducing the cost of drug development should make the continuing search for the therapeutic rationale of antibacterial dosing of mice and men worthwhile.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9455502     DOI: 10.1086/516284

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  757 in total

1.  In vitro and in vivo activities of amikacin, cefepime, amikacin plus cefepime, and imipenem against an SHV-5 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain.

Authors:  D Szabó; A Máthé; Z Filetóth; P Anderlik; L Rókusz; F Rozgonyi
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

Review 2.  Achieving an optimal outcome in the treatment of infections. The role of clinical pharmacokinetics and pharmacodynamics of antimicrobials.

Authors:  R C Li; M Zhu; J J Schentag
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

3.  Influence of Pharmacokinetic and Pharmacodynamic Principles on Antibiotic Selection.

Authors:  George G. Zhanel
Journal:  Curr Infect Dis Rep       Date:  2001-02       Impact factor: 3.725

4.  Assumed versus approved breakpoints.

Authors:  D A Preston; M R Turnak
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

5.  BTS Guidelines for the Management of Community Acquired Pneumonia in Adults.

Authors: 
Journal:  Thorax       Date:  2001-12       Impact factor: 9.139

Review 6.  Antifungal susceptibility testing: practical aspects and current challenges.

Authors:  J H Rex; M A Pfaller; T J Walsh; V Chaturvedi; A Espinel-Ingroff; M A Ghannoum; L L Gosey; F C Odds; M G Rinaldi; D J Sheehan; D W Warnock
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

7.  Pharmacodynamics, a tool for a better use of antibiotics?

Authors:  F Crokaert
Journal:  Intensive Care Med       Date:  2001-02       Impact factor: 17.440

8.  Evaluation of T-3811ME (BMS-284756), a new des-F(6)-quinolone, for treatment of meningitis caused by penicillin-resistant Streptococcus pneumoniae in rabbits.

Authors:  Masahiro Takahata; Hiroshi Yamada; Teiichi Morita; Shinichi Furubou; Shinzaburo Minami; Yozo Todo; Yasuo Watanabe; Hirokazu Narita
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

9.  Concentration-dependent selection of small phenotypic differences in TEM beta-lactamase-mediated antibiotic resistance.

Authors:  M C Negri; M Lipsitch; J Blázquez; B R Levin; F Baquero
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

Review 10.  In vitro antibacterial activity and pharmacodynamics of new quinolones.

Authors:  A Dalhoff; F-J Schmitz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-04-01       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.